Mycenax Biotech Inc.

Equities

4726

TW0004726005

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
43.55 ^TWD	-0.68%		-5.94%	+21.99%

Mar. 14	Mycenax Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 13	Mycenax Biotech Inc. Announces the Appointment of Li-Ju Yeh as Corporate Governance Officer	CI

Mycenax Biotech Inc. Announces Board Changes

February 19, 2024 at 02:57 am EST

Mycenax Biotech Inc. announced that the replacement of representative of juristic person of Director. Name and resume of the previous position holder: Hsiu-Yuan Lee, CEO, CIDC Consultants Inc. with Name of the new position holder: Yi-Hsin Lee, Vice President, CIDC Consultants Inc. as Director. Date of occurrence of change is February 19, 2024.

Latest news about Mycenax Biotech Inc.

Mycenax Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Mycenax Biotech Inc. Announces the Appointment of Li-Ju Yeh as Corporate Governance Officer	Mar. 13	CI
Mycenax Biotech Inc. cancelled the transaction announced on March 13, 2023	Mar. 12	CI
Mycenax Biotech Inc. announced that it expects to receive funding from Center Laboratories, Inc., JCR Pharmaceuticals Co., Ltd., Taiwan BioVenture Company, Jason Technologies Ltd	Mar. 12	CI
Mycenax Biotech Inc. Announces Resignation of Stacy Sun as Corporate Governance Officer, Effective on February 29, 2024	Feb. 27	CI
Mycenax Biotech Inc. Announces Board Changes	Feb. 19	CI
Mycenax Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Mycenax Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Mycenax Biotech Inc. Announces Resignation of Yu-Ching Chang as Financial and Accounting Officer, Effective on August 11, 2023	23-08-02	CI
Mycenax Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Mycenax Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI
Mycenax Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI
Mycenax Biotech Inc. announced a financing transaction	23-03-12	CI
Mycenax Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Mycenax Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Mycenax Biotech Inc. announced that it expects to receive TWD 1.659112761 billion in funding from JCR Pharmaceuticals Co., Ltd., Center Laboratories, Inc.	22-07-26	CI
Mycenax Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Mycenax Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-24	CI
Mycenax Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-11	CI
Mycenax Biotech Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI
Mycenax Adapts the Beacon Optofluidic System to Cell Line Development Services	21-05-17	CI
Mycenax Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-16	CI
Mycenax Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-29	CI
Mycenax Biotech Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-11	CI
Mycenax Biotech Inc.(GTSM:4726) added to S&P Global BMI Index	20-09-21	CI

Chart Mycenax Biotech Inc.

Duration

Period

More charts

Company Profile

Mycenax Biotech Inc. is a Taiwan-based company principally engaged in the development and manufacture of pharmaceutical products. Its products are derived from mammalian cell culture and microbial fermentation. Its products include TuNEX, LusiNEX, GranNEX and AiNEX. Its products are applied in treatment of brain cancer, psoriasis and renal cell carcinoma, among others. The Company is also engaged in the provision of chemical, manufacturing and control (CMC) technology and the operation of a current good manufacture practice (cGMP) biopharmaceutical factory. The Company mainly operates its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
MYCENAX BIOTECH INC.	+21.99%	275M
VERTEX PHARMACEUTICALS INCORPORATED	-2.70%	102B
REGENERON PHARMACEUTICALS, INC.	+1.89%	96.29B
ARGENX SE	+1.86%	22.18B
BIONTECH SE	-15.46%	21.2B
GENMAB A/S	-8.68%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-14.06%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.65%	13.97B
SAREPTA THERAPEUTICS, INC.	+32.94%	12.17B

Bio Therapeutic Drugs